Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-DOTA-TLX592
- Development stage
- Unknown
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A radiolabeled antibody drug, 64Cu-DOTA-TLX592 is a radioimmunoconjugate composed of a humanized, engineered monoclonal antibody (HuX592r) targeting the tumor-associated antigen prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer cells. The antibody is conjugated with the chelator DOTA and labeled with the positron-emitting isotope copper-64 (^64Cu), enabling detection by PET imaging. It is primarily developed as a diagnostic and dosimetry agent to predict therapeutic behavior for future use with therapeutic radionuclides such as actinium-225 (^225Ac). The drug demonstrates rapid blood clearance and hepatic elimination, favorable for targeted alpha therapy applications. Developed by Telix Pharmaceuticals, it is being investigated in Phase I clinical trials for metastatic prostate cancer[1][2][3][4][5].
- Other names
- copper Cu 64-DOTA-TLX592
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 64Cu-DOTA-TLX592.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-DOTA-TLX592.